91 related articles for article (PubMed ID: 6631169)
1. Nephelometric measurement of human serum amyloid P component (SAP).
Gertz MA; Skinner M; Cohen AS; Kyle RA
J Lab Clin Med; 1983 Nov; 102(5):773-8. PubMed ID: 6631169
[TBL] [Abstract][Full Text] [Related]
2. Nephelometric measurement of human serum prealbumin and correlation with acute-phase proteins CRP and SAA: results in familial amyloid polyneuropathy.
Connors LH; Gertz MA; Skinner M; Cohen AS
J Lab Clin Med; 1984 Oct; 104(4):538-45. PubMed ID: 6090552
[TBL] [Abstract][Full Text] [Related]
3. Measurement of murine serum amyloid P component by rate nephelometry.
Gertz MA; Sipe JD; Skinner M; Cohen AS; Kyle RA
J Immunol Methods; 1984 Apr; 69(2):173-80. PubMed ID: 6201557
[TBL] [Abstract][Full Text] [Related]
4. Agglutination of complement-coated erythrocytes by serum amyloid P-component.
Hutchcraft CL; Gewurz H; Hansen B; Dyck RF; Pepys MB
J Immunol; 1981 Mar; 126(3):1217-9. PubMed ID: 7462631
[TBL] [Abstract][Full Text] [Related]
5. Protein SAP (serum amyloid P-component) in Waldenström's macroglobulinaemia, multiple myeloma and rheumatic diseases.
Strachan AF; Johnson PM
J Clin Lab Immunol; 1982 Sep; 8(3):153-6. PubMed ID: 6813503
[TBL] [Abstract][Full Text] [Related]
6. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction.
Bijl M; Bootsma H; Van Der Geld Y; Limburg PC; Kallenberg CG; Van Rijswijk MH
Ann Rheum Dis; 2004 Jul; 63(7):831-5. PubMed ID: 15194579
[TBL] [Abstract][Full Text] [Related]
7. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical identification of amyloid, using an anti-human serum amyloid P component (SAP) antibody, is possible in ruminants but not in dogs and cats.
Hartig W; Leifsson PS; Nielsen OL
J Vet Med A Physiol Pathol Clin Med; 2005 Nov; 52(9):447-53. PubMed ID: 16268955
[TBL] [Abstract][Full Text] [Related]
9. Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infection, and malignancy as compared to normal serum.
Skinner M; Vaitukaitis JL; Cohen AS; Benson MD
J Lab Clin Med; 1979 Oct; 94(4):633-8. PubMed ID: 479670
[TBL] [Abstract][Full Text] [Related]
10. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and the acute phase response.
Gewurz H; Mold C; Siegel J; Fiedel B
Adv Intern Med; 1982; 27():345-72. PubMed ID: 7041546
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat.
de Beer FC; Baltz ML; Munn EA; Feinstein A; Taylor J; Bruton C; Clamp JR; Pepys MB
Immunology; 1982 Jan; 45(1):55-70. PubMed ID: 7056568
[TBL] [Abstract][Full Text] [Related]
13. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.
Hawkins PN; Rossor MN; Gallimore JR; Miller B; Moore EG; Pepys MB
Biochem Biophys Res Commun; 1994 Jun; 201(2):722-6. PubMed ID: 7516157
[TBL] [Abstract][Full Text] [Related]
14. Involvement of CD14 and toll-like receptor 4 in the acute phase response of serum amyloid A proteins and serum amyloid P component in the liver after burn injury.
Cho K; Pham TN; Crivello SD; Jeong J; Green TL; Greenhalgh DG
Shock; 2004 Feb; 21(2):144-50. PubMed ID: 14752288
[TBL] [Abstract][Full Text] [Related]
15. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid P-component as a marker of liver disease.
Levo Y; Shalit M; Tur-Kaspa R
Am J Gastroenterol; 1982 Jun; 77(6):427-30. PubMed ID: 7091128
[TBL] [Abstract][Full Text] [Related]
17. Acute phase reactants of mice. I. Isolation of serum amyloid P-component (SAP) and its induction by a monokine.
Le PT; Muller MT; Mortensen RF
J Immunol; 1982 Aug; 129(2):665-72. PubMed ID: 6806378
[TBL] [Abstract][Full Text] [Related]
18. Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains.
Baltz ML; Gomer K; Davies AJ; Evans DJ; Klaus GG; Pepys MB
Clin Exp Immunol; 1980 Feb; 39(2):355-60. PubMed ID: 7389204
[TBL] [Abstract][Full Text] [Related]
19. The relationship of a serum protein, C1t, to a common nonfibrillar constituent of amyloid (P component) as revealed by immunohistochemical studies.
Katz A; Weicker-Thorne J; Painter RH
Am J Pathol; 1977 Sep; 88(3):679-98. PubMed ID: 329683
[TBL] [Abstract][Full Text] [Related]
20. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses.
Ashton AW; Boehm MK; Gallimore JR; Pepys MB; Perkins SJ
J Mol Biol; 1997 Sep; 272(3):408-22. PubMed ID: 9325100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
